 AstraZeneca can get a boost from the probability that it will close out its US kidney damage lawsuit in New Jersey prior to the first bellwether case in March 2023, according to Citi. The UK pharma is one of several firms embroiled in US legal action over possible damage caused by proton pump inhibitor PPI heartburn drugs such as Nexium, launched by Astra in the US in 2001. 